SymBio Pharmaceuticals Limited
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥10,008M | ¥5,590M | ¥2,453M | ¥1,308M |
| Gross Profit | ¥7,600M | ¥4,411M | ¥1,873M | ¥947M |
| Operating Income | ¥1,964M | -¥812M | -¥3,877M | -¥4,441M |
| Pretax Income | ¥1,964M | -¥812M | -¥3,807M | -¥4,709M |
| Net Income | ¥1,179M | -¥1,963M | -¥3,833M | -¥4,776M |
| EPS | ¥29.77 | -¥49.19 | -¥85.00 | -¥95.12 |
| Operating Margin | 19.62% | -14.52% | -158.06% | -339.59% |
| Balance Sheet | ||||
| Total Assets | ¥10,433M | ¥8,170M | ¥4,968M | ¥3,867M |
| Total Equity | ¥8,506M | ¥7,210M | ¥4,198M | ¥1,272M |
| Total Liabilities | ¥1,927M | ¥960M | ¥771M | ¥2,595M |
| Cash | ¥6,283M | ¥6,517M | ¥3,964M | ¥2,884M |
| Interest-bearing Debt | - | - | ¥0M | ¥1,983M |
| Equity Ratio | 81.53% | 88.25% | 84.49% | 32.89% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 1.56 |
| Cash Flow | ||||
| Operating CF | ¥1,614M | -¥195M | -¥3,417M | -¥4,576M |
| Investing CF | -¥47M | -¥377M | -¥4M | -¥76M |
| Financing CF | ¥628M | ¥680M | ¥708M | ¥3,622M |
| Free CF | ¥1,567M | -¥427M | -¥3,463M | -¥4,658M |
| Efficiency | ||||
| ROE | 13.86% | -27.22% | -91.33% | -375.48% |
| ROA | 11.30% | -24.02% | -77.16% | -123.50% |
Latest IR Information
-
Unsecured Bond Facility Agreement and Issuance of the Second Unsecured Ordinary Bond (Private Placement) and Third-Party Allotment of the 70th and 71st Warrants and Conclusion of the Buyback Agreement
Setting up a unsecured bond facility of up to 5 billion yen with EVO FUND as the, issuer; issuing the Second Unsecured Ordinary Bond. Warrants for the 70th and 71st will be allocated to EVO FUND, with a revised exercise...
Read more -
SymBio Pharmaceuticals Co., Ltd. 2026 Fiscal Year December Quarter 2 Interim Financial Summary
For the interim period of the 2026 fiscal year, net sales were 469 million yen, operating loss was 3,635 million yen, ordinary loss was 3,608 million yen, and net loss attributable to owners of the parent was 3,619 million yen....
Read more -
Monthly status of exercise of the 58th and 66th stock acquisition rights issued through third-party allocation (with exercise price adjustment clause)
Disclosure of the monthly exercise status of stock acquisition rights issued via third-party allocation. Includes a detailed table defining exercised shares, exercise amount, issued shares, and other items constituting the exercise status. Monitoring future exercise trends and dilution impact is...
Read more -
【SymBio Pharmaceutical】Exercise of Stock Acquisition Rights in Large Volume｜July 2026
As of July 29, 2026, SymBio Pharmaceutical transferred 28,540 shares through the exercise of stock acquisition rights, bringing the total issued shares to approximately 76,434,210.
Read more -
Notice Regarding the Completion of Early Redemption of the First Unsecured Unsubordinated Bonds
Read more
Latest News (5 items)
Company Information
About
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
